These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 30007818)

  • 21. The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer.
    Tan HJ; Marks LS; Hoyt MA; Kwan L; Filson CP; Macairan M; Lieu P; Litwin MS; Stanton AL
    J Urol; 2016 Jun; 195(6):1724-30. PubMed ID: 26872841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Focal therapy for clinically localized prostate cancer.
    Marchetti P; Eggener S
    Arch Esp Urol; 2011 Oct; 64(8):815-22. PubMed ID: 22052762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation].
    Bonneux L
    Ned Tijdschr Geneeskd; 2005 Apr; 149(18):966-71. PubMed ID: 15903036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel method for the evaluation of uncertainty in dose-volume histogram computation.
    Henríquez FC; Castrillón SV
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1263-71. PubMed ID: 18313532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The future of endocrine treatment in early prostate cancer: concluding remarks.
    Schröder FH
    Eur Urol; 1999; 36 Suppl 2():27-30. PubMed ID: 10529563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts ("ICE").
    Reis LO; Billis A; Zequi SC; Tobias-Machado M; Viana P; Cerqueira M; Ward JF
    Aging Male; 2014 Jun; 17(2):66-71. PubMed ID: 24597940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement uncertainty analysis of low-dose-rate prostate seed brachytherapy: post-implant dosimetry.
    Gregory KJ; Pattison JE; Bibbo G
    Australas Phys Eng Sci Med; 2015 Mar; 38(1):71-81. PubMed ID: 25555753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI-guided focal therapy of prostate cancer.
    Mathew MS; Oto A
    Future Oncol; 2017 Mar; 13(6):537-549. PubMed ID: 27776423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A population-based model to describe geometrical uncertainties in radiotherapy: applied to prostate cases.
    Budiarto E; Keijzer M; Storchi PR; Hoogeman MS; Bondar L; Mutanga TF; de Boer HC; Heemink AW
    Phys Med Biol; 2011 Feb; 56(4):1045-61. PubMed ID: 21258137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance.
    Parker PA; Davis JW; Latini DM; Baum G; Wang X; Ward JF; Kuban D; Frank SJ; Lee AK; Logothetis CJ; Kim J
    BJU Int; 2016 Mar; 117(3):469-77. PubMed ID: 25714186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of the concept of focal therapy for prostate cancer.
    Tsivian M; Abern MR; Polascik TJ
    Oncology (Williston Park); 2013 Jan; 27(1):64-8, 70; discussion 70. PubMed ID: 23461042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of dose uncertainties in cumulated dose estimation compared to planned dose in prostate IMRT.
    Nassef M; Simon A; Cazoulat G; Duménil A; Blay C; Lafond C; Acosta O; Balosso J; Haigron P; de Crevoisier R
    Radiother Oncol; 2016 Apr; 119(1):129-36. PubMed ID: 26993416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of the uncertainties of a biological model and their impact on variable RBE proton treatment plan optimization.
    Resch AF; Landry G; Kamp F; Cabal G; Belka C; Wilkens JJ; Parodi K; Dedes G
    Phys Med; 2017 Apr; 36():91-102. PubMed ID: 28410691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to select the right patients for focal therapy of prostate cancer?
    Passoni NM; Polascik TJ
    Curr Opin Urol; 2014 May; 24(3):203-8. PubMed ID: 24625428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.
    von Hardenberg J; Westhoff N; Baumunk D; Hausmann D; Martini T; Marx A; Porubsky S; Schostak M; Michel MS; Ritter M
    Urol Oncol; 2018 Sep; 36(9):401.e1-401.e9. PubMed ID: 30093211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-modality functional image guided dose escalation in the presence of uncertainties.
    Alber M; Thorwarth D
    Radiother Oncol; 2014 Jun; 111(3):354-9. PubMed ID: 24880742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer therapy: finding the right balance.
    Saad F
    Lancet Oncol; 2012 Feb; 13(2):119-20. PubMed ID: 22112794
    [No Abstract]   [Full Text] [Related]  

  • 38. Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence.
    Weldon VE; Tavel FR; Neuwirth H; Cohen R
    J Urol; 1995 Sep; 154(3):1074-7. PubMed ID: 7543602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irreversible electroporation, a new modality in Focal Therapy for prostate cancer.
    Scheltema MJ; van den Bos W; Wagstaff PG; Postema AW; de Bruin DM; Laguna Pes MP; de la Rosette JJ
    Arch Esp Urol; 2016 Jul; 69(6):337-44. PubMed ID: 27416637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focal therapy in prostate cancer: A review of seven common controversies.
    Bass EJ; Ahmed HU
    Cancer Treat Rev; 2016 Dec; 51():27-34. PubMed ID: 27846402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.